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ABSTRACT
The acquired immunodeficiency syndrome (AIDS) caused by human immuno
deficiency virus (HIV) is still a significant public health problem. In the
United States approximately 1,000,000 people live with HIV/AIDS infection. 4 The
recommended treatment is HAART (highly active antiretroviral therapy) . The HAART
treatment is very complex, because of a large number of prescribed drugs in a regimen,
frequent dosing and also a number of side effects. In HIV management precise
adherence 13• 26 to the prescribed medication regimen is the key for the maximal viral
suppression and improved health status, and the only way to turn this deadly disease
into a manageable chronic disease. The importance of many factors associated with
medication adherence, including patient characteristics, disease characteristics,
medication regimen characteristics, and the patient-provider relationship has been
documented. One of the aspects of the complexity of the prescribed regimen is the
number of medications in the regimen.
Results: The number of medications did not show association with medication
adherence. Patients on a more complex antiretroviral medication regimen did not miss
higher percent of prescribed medication, and we may not discriminate between
adherent and non-adherent patients only based on a number of prescribed antiretroviral
medication. Also the variables number of side effects and how long ago HIV positive
were negatively associated with medication adherence.
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INTRODUCTION
Epidemiology of HIVI AIDS infection

The

acquired

immunodeficiency

syndrome

(AIDS)

caused

by

human

immunodeficiency virus (HN) is still a significant public health problem. From 1981 ,
which marked the beginning of the HIV pandemic, throughout the following 20 years,
HIV/AIDS has spread worldwide affecting every single country. 1 Epidemiological
picture of HIVI AIDS infection around the world for the last year has the following
indicators; more than 5 million new cases of HIV infection had occurred in 2000.
Estimated prevalence tells that currently around the world about 36 million people live
with HIVI AIDS infection. The WHO also has reported that AIDS caused 22 million
deaths .2 In the United States approximately 1,000,000 people live with HIV/AIDS
infection. 3 The incidence of HIV infection is about 40,000 cases each year. 3 In this
country more than 420,000 people have already died from AIDS. 4
Adherence-key factor in HIV/AIDS treatment

Current therapeutic options for HNI AIDS patients include more than 15 antiretroviral
drugs, commonly grouped in the three classes as: nucleoside reverse transciptase
inhibitors (NRTD, nonnucleoside reverse transcriptase inhibitors (NNRTD and
protease inhibitors (PI). 5 ' 6' 7 ' 8 From 1996 the highly active antiretroviral therapy
(HAART) has been used as a standard of care for symptomatic as well asymptomatic
HN positive patients. 5 •9 •10 The HAART treatment is very complex, because of a large

number of prescribed drugs in a regimen and frequent dosing. 9 •10 Also a number of

(
side effects, drug interactions, toxicities and also very specific food restrictions make
this treatment not only complex but also very demanding for the patients and
consequently difficult for lifetime precise adherence. 5•9• 10•11 •12 •13•14 Previous research
suggests that in general patients with more complex medication regimen are less
adherent to the prescribed regimen. 12' 15 •16 In contrast, several other studies reported
increased medication adherence with an increase in a number of prescribed medication
in a regimen. 17•18• 19 Several studies did not find an association between medication
regimens' complexity and patient medication adherence.20 •2 1 Because previous
research reported uncertain and inconclusive findings; there has been a need for more
research on adherence and medication regimen complexity in HIV population. Clear
understanding of this issue is necessary, and may have important implications for
further treatment of HIV positive patients, as well as further incentive for
pharmaceutical industries.
Adherence to a prescribed medication regrmen reqmres taking medication as
prescribed consistently. 22 Adherence or compliance was defined by Fisher as 'a
concept used to measure' 23 positive patients' behavior 'in meeting their therapeutic
goals. ' 23 In HIV management precise adherence 7' 9' 12' 24 to the prescribed antiretroviral
medication regimen is the key for the maximal viral suppression and improved health
status, longer and better quality of life, and the only way to turn this deadly disease
into a manageable chronic disease. 7' 12' 22 ' 24' 25 Poor medication adherence and irregular
use of prescribed antiretroviral medication with inadequate drug concentration may
result in resistance and consequently reduced treatment options for HIV positive

2

(
patients.

8 12 13 22 26
• ' • •

Although research did not define how frequently an HIV positive

patient can miss antiretroviral medication before resistance develops less than optimal
results were reported with medication adherence lower than 90%.

9 25 34
• •

In addition

because HIV resistant strains might be transferred to others, poor medication
adherence in HIV/AIDS management may have a devastating impact on a public
health.

16 22 24 25 27
• • • •

Thus, strict adherence to the prescribed antiretroviral medication

regimen is essential and estimation of factors associated with medication adherence in
HN population present a crucial issue in HIV management and current research.

Previous research has reported different medication adherence rates in the HIV
population. Wenger et al. reported 57% adherence to prescribed medication regimen
19

,

Willey et al. reported 86% adherence, 29 and Samet et al. reported 67% adherence30 .

Poor adherence to the prescribed antiretroviral medication regimen of 60% and 42%
were reported by Eldred JL, et al. 31 and Muma et al. 32
Medication non-adherence also causes higher costs of HIVI AIDS treatment because of
increased number of complications and development of opportunistic infections,
hospitalizations, and finally increased mortality of the HIV infected patients. 13
Consequences of medication non-adherence are the most obvious in HIV population.
Hogg et al. reported that for every 10% decrease in adherence, the mortality rate
increases by 16%.

33

Few studies have reported direct relationships between the level

of patients' adherence to a prescribed antiretroviral therapy and viral load suppressions
as well as CD4 cell count status. 10• 25 •34

3
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Factors associates with adherence:
Previous research has reported a number of different factors associated with
adherence to the prescribed medication regimen.

15 22 35
' '

Adherence is a very complex

phenomenon, and may be influenced by many different factors. These factors are
commonly grouped as:
•

Patient characteristics

•

Disease characteristics

•

Medication regimen characteristics

•

Patient-provider relationship characteristics 12 ' 15

A. Patient characteristics: include age, gender, race, employment, occupation,
income, health insurance, living arrangements, marital status, number of children, and
social support. 15 Not all patients' characteristics influence medication adherence in
the same way. Demographics do not seem to have predictive value for medication
. dm
. a num b er of stud"ies.12 ' 14 ' 17' 19 ' 20 ' 22
adh erence, a1though t hey have b een examme
Older age, gender, race, income or employment has been reported to influence
1y, and fimd"mgs are genera11 y mconc
.
1us1ve.
. 14 ' 15' 16
.
adherence b ut not consistent

Recently a few studies have found that low literacy contributes to poor medication
adherence.

52 53
'

Patient characteristics, most frequently reported to positively

. adh erence, me
. 1ud e socia
. I support fr om f:am1·1y and fr.iends. 12 '22 ' 30
i"nfluence med.icat10n
Also optimism and trust in prescribed antiretroviral treatment, and belief in successful
outcomes as well as knowledge about antiretroviral medication, and knowledge about

4

f

the importance of strict adherence in the treatment with antiretroviral medication lead
· regnnen.
·
12303
. is
. very
' ' 1'39 H uman bh
e av1or
to b etter adh erence to prescn·bd
e med.icat10n
complex and a number of psychosocial factors has a significant influence on
medication adherence. A number of studies have found that psychological problems,
lifestyle such as homelessness, alcoholism or drug abuse, contribute to medication
non-adherence.

16, 19,20,2 1,22,24,29,30,34

B. Disease characteristics : include symptoms, duration, diagnosis, number of
hospitalizations, severity, and extent of disability. 15 Disease characteristics such as
lack of symptoms or long term treatment usually influence medication adherence
negatively. 15 Previous studies have reported poor medication adherence in both
long-term treatments as well as short-term treatments with an average of fifty-percent
adherence. 15 ' 36 Even poorer medication adherence rates are common in preventive
treatment or treatment of asymptomatic patients. 36 ' 37 Certain diagnoses such as
psychiatric illnesses, depression, and mental disorders are commonly associated
with problems oflow medication adherence. 16' 24 ' 38 The literahrre regarding other
disease characteristics and medication adherence is inconclusive.

C. Medication regimen characteristics : include number of medications, type of

medication, side effects, number of doses, duration and cost. 15 Many studies reported
decreased medication adherence as the regimen became more complex and the number
of prescribed medications increased. 12' 15 ' 16 ' 37 ' 39 Several studies found quite the
opposite, increased adherence as the number of prescribed medications increased.

5

r

I7

. . 11y non-s1gru
. .fiicant or mcons1stent
.
.
'18' I 9'30 Qther researc hers reporte d stahstlca

associations between number of prescribed medications and medication adherence.
2021404
· may m
· fl uence adh erence as we11 as med.icahon
·
' ' ' 142s1
' ' The type o f med.icat10n
class. 16' 18 '21'39 '40 Treatments with a number of side effects were reported as a cause of
poor adherence to the prescribed medication regimen. 12 ' 16·43 Dosage frequency
influences adherence negatively; as the number of prescribed doses increases,
adherence to the prescribed medication regimen is reported to decrease. 12 ·18' 21·
40,42,44,4S

D. Patient-Provider relationship characteristics: have been evaluated in a number
. IS24314042
.
f;actor th at m
. fl uences patient
.
o f studies.
' ' ' ' '46 p oss1"bl y th e most important
medication adherence is the patient physician relationship .22 '37 '46 Friendly, respectful,
and long-term relationships between a patient and his/her physician is a very important
part of the success of both the therapy and patient adherence.ss The physician should
provide patients with detailed information about the disease and medication, and
provide written information about antiretroviral medication use. Physicians '
knowledge and experience in the treatment of HIV positive patients may generate
1247
higher patient trust and confidence and positively influence adherence. ' Other
healthcare providers such as nurses or pharmacist's, who provide clear explanations
about treatment options may also influence patients medication adherence positively as
well.

6
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Methods of adherence measurement:

In a search for the best and the most accurate measure of medication adherence
researchers develop a number of different methods. Commonly these methods are
grouped as direct or indirect. Directly we measure medication adherence by
monitoring medication use by patients, and by testing blood and urine for the presence
of drugs, metabolite, or drug markers. 15 ' 38 '48'49 The disadvantage of these methods is
that they do not give information about Jong-term medication use behavior28 . Although
direct methods probably have a higher sensitivity and specificity than indirect
methods, they are more expensive and more inconvenient for the patients. 49 Indirect
methods include pill counts, physician assessment, and self-reported adherence to a
prescribed medication regimen, prescription refill records, and electronic monitoring.
11 ,12, 15 ,38,48,49

A. The pill count method is based on the count of returned pills. This method was

very frequently in use in older research literature. The major disadvantage of this
method is unreliability. Because patients may not return all unused pills, this method
may be misleading and result in overestimated adherence.
B. Physician assessment provides inaccurate estimates of patient adherence, and with

this method the adherence rate is generally overestimated. 38•48•49
C. The self-report method includes questionnaires, diaries, and patients' interviews.
21 46
•

Questionnaires are often used in research because they are relatively simple and

fast way to collect data about small or large populations. Some researchers consider
patients' self-report as accurate measure of patient adherence, and others believe that

7

(
self-reported data overestimates adherence. 25 ' 33 ' 48 ' 50 A self-report is more convenient
for the patients, and less expensive than other measures. 24 With cooperative patients,
who are willing to disclose their behavior, self-report has the potential to be an
accurate measure of patient adherence. 24
D. The prescription refill records method is based on the use of pharmacy records,
and gives unique opportunity to explore adherence usually in a larger population, and
usually over longer periods of time. The disadvantage of this method is that we know
that prescription was filled, but we do not know did actually patient use the medication
as prescribed.
E. Electronic monitors are method based on use of the computerized drug containers.
Electronic monitors provide data with dates as well as time intervals of each opening
of the bottle. Electronic monitors use may also overestimate the adherence rate
because we know that bottle was opened but we do not know whether the prescribed
medication was used. 48 They are also expensive and impractical for large populations
as well as multi-drug regimens . For some forms of medication electronic monitors
cannot be used. Also because of awareness that their behavior is monitored patients
may be more adherent. Because there is no gold standard perhaps the most accurate
estimate of medication adherence may be obtained by using several methods in the
same study, which also gives an opportunity for reliability and validity comparison
between the measures. 11 ' 36 ' 48

8
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STATEMENT OF PURPOSE
A review of the literature shows the importance of precise and strict adherence to
complex antiretroviral regimens in the HN population. The importance of many
factors associated with adherence, including patient characteristics, disease
characteristics, medication regimen characteristics, and the patient-provider
relationship characteristics have been documented. The primary objective of this study
is to analyze and estimate the point prevalence of HN positive patients' adherence to
complex antiretroviral medication regimens and to examine the association of the
following factors with adherence:
•

Medication regimen complexity as a predictor of medication adherence while
controlling for patient characteristics, disease characteristics, and medication
regimen characteristics.

The secondary objective is to explore other potential predictors of medication
adherence. The hypothesis is that a number of medications may influence patients'
medication adherence. Patients on a more complex multi-drug regimen very likely will
be less adherent to the prescribed medication regimen than patients on a less complex
drug regimen. The patients on a more complex antiretroviral regimen, including a
larger number of prescribed medications very likely will miss more doses of
prescribed medication and demonstrate the poorer adherence to the prescribed
antiretroviral medication regimen.

9
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METHODOLOGY
Study Design
This is a descriptive, cross-sectional study of self-reported medication adherence to
prescribed HIV related medication regimen.
Study Sample
The study sample consists of 145 participants, all diagnosed as HIV positive patients.
A patients' eligibility to participate in this study was 1) over 18 years of age, 2) ability
to read and write English, and 3) currently using an antiretroviral medication, or
medication for HIV related complications. The study sample was not random sample.
All study participants were patients attending clinics. For participation, each person
received $20.
Data Collection
Data was collected in Rhode Island and Massachusetts at the Miriam Hospital
Immunology Center, the Stanley Street Treatment Center, and the Veterans Affairs
Medical Center. The physicians from each clinical site asked HIV positive patients for
consent to participate in the study. All data was collected by a self-reported
questionnaire. Questionnaires were distributed to most patients at the clinic, with the
option to complete the questionnaire at the clinic or at home and to bring it or mail it
back. Fifteen study participants, (10.34%) were incarcerated and questionnaires were
delivered to them in prison. A research assistant was available at both sites to respond
to any questions regarding the self-administered questionnaires, and with the pictures

(

and names of all HIV- related medications. HIV positive patients filled out the self-

10
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reported questionnaire during the year 1996-1997 (see appendix). From the six
sections of the questionnaire titled 'Managing Your Medication Questionnaire' only
section I 'Background Information' and section II 'Medication History' were used in
the analysis, (Willey, Unpublished data).

Measures:
The questionnaire collected information about the following:

A. Patients' characteristics: age, gender, health status, race, education, employment,
living arrangements, number of people in household, number of children, adult
children nearby, emotional support from family and friends, financial support from
family and friends, physical assistance and place to stay, number of people that you
have told about HIV infection, health insurance, income, and distance from treatment
center, anyone to reminds about medications, mood status and coping skills (attitude
toward antiretroviral medication).

B. Disease characteristics: bodily pain in the past 4 weeks, pain interference with
work in the past 4 weeks, days in bed in the past 2 weeks, number of hospitalizations
in the past year, how long ago diagnosed, how got HIV infection, CD4 cell count last
tested.

C. Medication regimen characteristics: number of medications, medication class,
how often use medications, how long on medication, drug holidays or discontinuation
of prescribed medication for more than 3 days, number of side effects, number of
doses missed in the past week, number of doses missed in the past month, number of

11
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doses missed in the past three months. Questions about the number of doses missed
were asked in a nonjudgmental manner. Participants were asked questions such as:
"Sometimes it is difficult to take prescribed medicine all the time. During the past
month, about how many times did you miss a dose of medication 1?" The same
question was asked for each drug in a patients' regimen. HN positive patients were
asked about the number of doses missed in the previous week, as well as the previous
month, and the previous three months.
D. Patient-Provider relationship characteristics: the most helpful health care

provider, and questions about medication use.
Method

The total number of prescribed HN related medications was calculated for each
participant; a larger number of prescribed medications corresponds to a more complex
regimen. The participants of this study were considered absolutely adherent (100%) to
prescribed antiretroviral therapy if they did not report missing any doses of prescribed
regimen in the previous month. Dependent variable medication adherence was
calculated using the following formula: {(total# of doses prescribed I total# of
medication) - (total #of doses missed) I total# medication)} I (total# of doses
prescribed I total# of medication)* 100. Consequently, a higher percent of doses
missed in the past month correspond to a higher level of medication non-adherence.
With multiple ANOV As the participants who reported 100% adherence were
separated as a sample and were used for comparison with the non-adherent sample.

12

Statistical Analvsis:

Data was analyzed using Multiple Regression Analysis with SAS program (Statistical
Analysis Software), Version 8.0. The computer facilities and the library at the
University of Rhode Island was used for the data analysis as well as for the all
necessary research work. Data were checked for the accuracy of the data entry and for
the basic assumptions of linearity, normality, and homoscedasticity. SAS procedures
proc mean and proc plot were used to check for outliers and linearity assumption of
all. Collinearity and singularity was checked also. The dependent variable, selfreported medication adherence (percent of doses taken), in the past month was used in
analysis because of the least skewness and kurtosis compared to self-reported
medication adherence in the past week or self-reported adherence in the past three
months. Also one month was considered as better time period for the evaluation of
medication taking behavior compared to one-week period. Recall bias was less likely
in a period of a month compared to three months period. Because of severe nonnormal distribution logarithmic transformation was performed on the dependent
variable medication adherence. Variables were considered significant predictors for
the p-value below 0.05. If independent variables were categorical then independent
variables were dummy coded.
The Questionnaire was designed to ask about the number of doses missed in the
previous month for each medication in patients' regimen; from the first drug in the
regimen to the sixth drug in a regimen. But the questionnaire was not designed to ask
about the number of doses missed for the regimen of 7 or more drugs. Seven study

13
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participants, (5%) were on the regimen of 7 or 8 drugs. Because most study
participants, (71 %) were on regimen of four or less than four drugs they did not
respond on the questions about the number of doses missed in the previous month for
the fifth or sixth drug in a regimen. Because information on the number of doses
missed in the previous month was missing for approximately 80% of variables for the
fifth or sixth drug in the regimen was not used in the analysis. This is illustrated in
Table 1. In accordance with this all computations were performed for the regimen of
four or less than four drugs. The variables to be evaluated included:

Dependent variable:
Two dependent variables were created. The first dependent variable medication
adherence was calculated for all study participants using the following formula:

A. Medication adherence, (percent of doses taken in the previous month):
0-100% (continuous), was defined and calculated as:
{(total # of doses prescribed I total # of medication) - (total # of doses missed) I total
# medication)} I (total # of doses prescribed I total # of medication)

* 100.

Medication adherence was calculated for the regimen of four or less than four drugs in
the regimen.
The second dependent variable was calculated only for the study participants who
reported that they had missed their medication. Consequently study participants who
reported that they never missed their medication were not included. Medication
adherence was defined and calculated as:

14
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B. Medication adherence, (percent of doses taken in the previous month):
0 - 99% (continuous), was defined and calculated as:

{(total #of doses prescribed I total# of medication) - (total #of doses missed) I total
# medication)} I (total # of doses prescribed I total # of medication)

* 100.

Medication adherence was calculated for the regimen of four or less than four drugs in
the regimen.
Independent variables:
A. Independent variables grouped as Patient Characteristics:

•

Age (continuous)

•

Race (categorical)
1 - Non-White

0 - White
•

Education (continuous)

•

Annual Income (categorical)
1 - <$ 24,000
0 - > $25,000

•

Employment (categorical)
1 - Full-time/Part-time
0 - Not employed

•

Health Status (categorical)
1 - ExcN g/Good

15
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0 - Fair/Poor
•

Number of family and friends that you can count on for physical assistance or
place to stay. (continuous).

B. Independent variables grouped as Disease characteristics
•

Bodily pain in the past 4 weeks (ordinal)
1 - None (Very mild/Mild/Moderate)
0 - Pain (/SevereN ery Severe)

•

Number of hospitalizations in the past year (continuous)

•

Days in bed in a last 2 weeks (continuous)

•

CD4 cell count last tested (categorical)
1 - Greater than 500
0 - Less than 500

•

How long ago diagnosed HIV positive (categorical).
1- >l year
0- <l year

C. Independent variables grouped as Medication regimen characteristics
•

Total number of prescribed medication (continuous); 1- 4
SumofQillX+QII2X+Qil3X+Qil4X

•

How long on HIV related medication (categorical)
1 - <= l year
0 ->l year

•

Number of side effects (continuous)

16

Sum of A: nausea, B: dizziness, C: vomiting, D: abdominal pain, E: diarrhea,
F: shortness of breath, G: muscle aches, H: fatigue, I: tingling in hands/feet,
J: numbness in hands/feet, K: headaches, L: anxiety/worry, M: depression, N: rash,
0: sensitivity to sun.
Preliminarily multiple regression analyses were performed, on each separate group of
factors most likely associated with adherence to prescribed medication regimen.
Multiple regression analyses were performed for: predictors ' group patient
characteristics, predictors group disease characteristics, and predictors group
medication regimen characteristics. Stepwise Multiple Regression analysis including
the factors most highly associated with medication adherence from each group, as well
as all other factors was carried out to define the best fit for the final model.
•

Multiple regression analysis model for the dependent variable Medication

Adherence(% of doses taken, 0 -100%) vs. the independent variable group:
patient characteristics.
Medication Adherence = Age +Race + Education + Employement + Health Status
+ Annual Income+# of People for Physical Assistance/Place to stay.
•

Multiple regression analysis model for the dependent variable Medication

Adherence(% of doses taken, 0- 99%) vs. the independent variable group:
patient characteristics.
Medication Adherence = Age + Race + Education + Employement + Health Status
+ Annual Income +# of People for Physical Assistance/Place to stay.
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•

Multiple regression analysis model for the dependent variable Medication

Adherence(% of doses taken, 0 -100%) vs. the independent variable group:
disease characteristics predictors.
Medication Adherence = Pain during past 4 weeks +Number of hospitalizations
+ Days in bed + How long ago diagnosed + CD4 cell count.
•

Multiple regression analysis model for the dependent variable Medication

Adherence(% of doses taken, 0- 99%) vs. the independent variable group:
disease characteristics predictors.
Medication Adherence = Pain during past 4 weeks+ Number of hospitalizations
+ Days in bed + How long ago diagnosed + CD4 cell count.
•

Multiple regression analysis model for the dependent variable Medication

Adherence(% of doses taken, 0-100%) vs. the independent variable group:
medication regimen characteristics.
Medication Adherence = Total nun1ber of medications + Number of side effects
+ Duration of medication use.
•

Multiple regression analysis model for the dependent variable Medication

Adherence(% of doses taken, 0- 99%) vs. the independent variable group:
medication regimen characteristics.
Medication Adherence = Total number of medications + Number of side effects
+ Duration of medication use.
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•

Stepwise Multiple Regression Analysis model for the dependent variable

Medication Adherence(% of doses taken, 0 -100%) vs. the independent
variables grouped in the final model.
Medication Adherence =Total number of medications +Number of side effects
+ Health insurance +Number of Children + How long ago diagnosed as HN positive.
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RESULTS

A: Patient Characteristics

Detailed demographics of this study population are given in Table 2. The mean age of
the study population was 39 ± SD 7; (range 24-57 years). The study sample was
predominantly White, (63%). A majority of the study participants (71 %) were males.
A high school education or less was reported by 67% of the study population. A
majority of the study participants were not currently employed; 72% reported that they
do not work. 59% reported an annual income of less than $15,000. A significant
number, (82%) reported lack of health insurance. In general, this study sample
reported a high level of social support. About 60% of the sample reported feeling very
or fairly confident that family or friends would continue to help with everyday needs.
About 95% of the study participants reported that they have told all or most of their
friends or relatives about their HIV status Living arrangements that include partners,
spouses, other adults, parents, or their children were reported by 70% of the study
sample. Approximately half of the sample reported that they have children. Also about
50% of the study participants reported that they have somebody who lives close to
them to remind them about the use of the prescribed medications. 39% reported belief
that they got HIV through IV drug use; the rest reported homosexual or heterosexual
contact as a transmission risk.
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B: Disease characteristics
In general, a majority of the sample population, (73%) reported excellent, very good,

or good health status. Also 63% reported that they had never been hospitalized. Only
13% of study participants reported severe or very severe bodily pain. Almost half,
46%, confirm that they never feel so weak that they need to spend a day in a bed. The
majority, 63%, reported long duration of disease; they had been diagnosed 5 years or
longer ago. In this study population basically 43% had developed AIDS, because 13%
reported a CD4 cell count less than 50, and 30% reported a CD4 cell count between 50
and 200. Table 3 shows the frequency of indicators of health status.

C: Medication regimen characteristics

The mean number of prescribed medications was 3.7 drugs. Prescribed HIV related
medications regimen range from monotherapy to 8 drugs therapy. 6 study participants,
or 4%, were on monotherapy, 30 study participants, or 21 % were on 2-drug therapy,
and 41, or 28%, were on 3-drug therapy. 24 study participants or 17% were on a more
complex regimen of 4 drugs. 44 study participants or 30% were on a regimen of 5 and
more drugs. Antiviral medications were prescribed for almost all study participants
(99%); 50% had protease inhibitors in their regimen, and 56% additionally used
antinfective medication for HIV related complications. The most commonly prescribed
antiviral medications in this study population were: lamivudine or epivir (3TC),
prescribed for 121 patient or 83%; then stavudine or zerit (D4T), prescribed for 69
patients or 49%; and zidovudine or retrovir (AZT), prescribed for 65 participants or
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45%. Among antiinfectives, bactrirn or septra (Trimethoprirn) was the most commonly
prescribed drug, for 67 patients or 46%. Among protease inhibitors, the most
commonly prescribed drug was Indinavir (Crixivan), prescribed for 58 participants or
40%. The most common frequency of dosing was two or three times a day for each
drug in a regimen. The prescribed regimens did not cause any side effects in 26% of
study population. The rest confirm that they experienced from one to a number of side
effects. Table 4 shows the frequency of indicators of medication regimen.

D: Patient-Provider relationship characteristics
Physicians were described as the most helpful health care providers. If study
participants have questions about their medications, 91 % ask their physicians, 31 % ask
a pharmacist, and 30% a nurse. Patient provider relationship characteristics are shown
in Table 5.

E: Medication adherence
Almost half of the study sample reported that they had never missed a dose of
prescribed medication. There appears to be a significant difference in reported strict,
100% adherence. 70% of study participants reported 100% medication adherence in
the past week for the first drug in a regimen. However, only 46% HIV positive patients
reported 100% adherence with prescribed medication in the past month, and 41 % of
study participants reported 100% medication adherence in the past three months. A
I

summary of this information is presented in table 6.
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In this sample about one half (48%) of study participants reported medication non-

adherence. They reported that they had missed from 1 to 35 doses of prescribed HIV
related medication in the previous month. Table 6A present percent of those who
reported non-adherence, (1-35 doses missed), as well as percent of those who reported
strict adherence, (0 doses missed), and percent of missing data.
A significant number of study participants, reported unintentional non-adherence 29 ;
46% reported forgetfulness as a reason for missing a dose of prescribed medication.
Also a high number reported intentional non-adherence 29 ; 25% reported sometimes
being careless about taking prescribed antiretroviral medication regimen. 19% admit
that sometimes they stop the use of prescribed medication. 14% reported drug holidays
for 3 or more days.
The mean number of prescribed doses missed in the previous month was 5 doses. Selfreported mean medication adherence in the previous month was high and was
calculated to be 97%, with a minimum of 58% and maximum of 100%. The mean
medication adherence in the past week was 95%, and the mean medication adherence
in the past three months was 98%.

F: Multiple Regression Analvsis and Stepwise multiple Regression Analysis

Multiple regression analyses were performed for the following models: predictors'
group patient characteristics, predictors' group disease characteristics, predictors'
group medication regimen characteristics and Stepwise multiple regression analysis for
the final model.
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Table 7: The result of multiple regression analysis for the dependent variable,
Medication Adherence(% of doses taken, 0- 99%) Vs. the independent variables
group patient characteristics:
The model was significant F7, 67 = 2.71 (Pr> F 0.0154), and R 2 = 0.2208. This suggest
that 22.08% of the variability in the dependent variable may be explained by the
model. The result of the multiple regression analysis showed that race (Non-White)
and education had significant positive association with medication adherence. Other
variables such as age, employment, annual income, health status, and number of
people available for physical assistance did not show significance at the 0.05 level.

Table 7A: The result of multiple regression analysis for the dependent variable,
Medication Adherence(% of doses taken, 0-100%) vs. the independent
variables group patient characteristics:
The model was not significant F7, 122 = 1.72 (Pr> 0.1103), and R 2 = 0.0898. This
suggest that 8.98% of the variability in the dependent variable may be explained by the
model. The result of the multiple regression analysis showed that race had significant
association with medication adherence. Other variables such as age, employment,
education, annual income, health status, and number of people available for physical
assistance did not show significance at the 0.05 level.

Table 8: The result of multiple regression analysis for the dependent variable,
Medication Adherence (% of doses taken, 0 - 99%) vs. the independent variables
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Group disease characteristics predictors:
The model was not significant F 5, 70 = 0.27 (Pr >0.9273) and R 2 = 0.0190. None of the
predictor variables such as number of days in bed, pain interference with work, bodily
pain, how long diagnosed as HIV positive or CD4 cell count showed significant
relationship with dependent variable medication adherence.

Table SA: The result of multiple regression analysis for the dependent variable,
Medication Adherence(% of doses taken, 0-100%) vs. the independent
variables group disease characteristics predictors:
The model was not significant f 5, 12 8 = 0.72 (Pr > 0.6122) and R 2 = 0.0272. None of the
predictor variables such as number of days in bed, number of hospitalizations, bodily
pain, how long diagnosed as HIV positive or CD4 cell count showed significant
relationship with dependent variable medication adherence.

Table 9: The result of Multiple regression analysis for the dependent variable,
Medication Adherence(% of doses taken, 0- 99%) vs. the independent variables
group medication regimen characteristics:
The model was not significant F4 , 75 = 1.89 (Pr > 0.1386) and R 2 = 0.0703 . None of the
variables grouped as medication regimen characteristics, including number of
medications, number of side effects, or duration of treatment, showed significant
association with dependent variable medication adherence.

Table 9A: The result of Multiple regression analysis for the dependent variable,
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Medication Adherence(% of doses taken, 0-100%) vs. the independent
variables group medication regimen characteristics:
The model was not significant F 4, 134 = 2.24 (Pr > 0.0867) and R 2 = 0.0477. The
variable side effect showed statistically significant association with dependent variable
medication adherence in contrast to the variables number of medications, or duration
of treatment.

Table 10: The result of Stepwise Multiple Regression Analysis for the final model
for dependent variable Medication Adherence(% of doses taken, 0 -100%) vs.
the independent variables grouped in the final model:
The final model was significant F 5, 134

=

3.44 (Pr> 0.0059). In this model R 2 = 0.1138

suggesting that 11.38% of the variability in dependent variable medication adherence
may be predicted by the model. The variable number of side effects and number of
children showed negative statistically significant association with the variable
medication adherence. The variable total number of medication did not show
significant association with medication adherence; p-value was non-significant,
0.0921. Other variables in the model such as How long ago diagnosed as HIV positive,
and Health insurance also did not show statistically significant association with
medication adherence in the final model.
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Table 1: Percent of HIV Positive Patients Who Responded
On the Questions About the # of Doses Missed
Medication #

Past week

Past month

Past 3 months

Medication #1
missing data

97.93%
2.07%

94.48%
5.52%

90.34%
9.66%

Medication #2
missing data

91.03%
8.97%

87.59%
12.41 %

.. ,. 86.21%
13.79%

Medication #3
missing_ data

68.97%
31 .03%

69.66%
30.34%

68.28%
31.72%

Medication #4
missing data

34.97%
65 .03%

34.97%
65.03%

33.57%
66.43%

Medication #5
missing data

20.28%
79.72%

19.58%
80.42%

19.58%

80.42%

Medication #6
missing data

10.49%
89.51%

10.49%
89.51%

10.49%
89.51%

*Past Week(% who responded about# of doses missed/past w.)
*Past Month(% who responded about# of doses missed/past m.)
*Past 3 Months (% who responded about# of doses missed/past 3 m.
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Table 2: Patient Characteristics
Age (mean ) 39 +/- 7
Gender
Female
Male

Participants #
42
102

Participants%
29%
71%

Race
White
African-American
Hispanic
Native American
Other

Participants #
91
23
16
4
10

Participants%
63%
•:16%
11%
3%
7%

Education
< 12 years
12 years
> 12 years

Participants #
48
46
51

Participants %
33%
32%
35%

Employment
Not employed
Full-time
Part-time

Participants #
105
22
17

Participants %
72%
15%
12%

Health Insurance
No Health Insurance
Health Insurance

Participants #
119
23

Participants %
82%
16%

Annual Income
< 15,000
15,000-24,000
25,000-34,000
35,000-44,000
> 45,000

Participants #
85
26
9
12
4

Participants %
59%
18%
6%
8%
3%
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Table 2: Patient Characteristics cont.
Living Arrangement
With Others
Alone

Participants #
101
44

Participants%
70%
30%

#Children
No
Yes

Participants #
66
79

Participants %
46%
54%

Social Support
Very or fairly confident in suppor
Somewhat confident
Less than somewhat or not at al

Participants #
88
24
29

Participants %
61%
17%
20%

Got HIV Infection
IV Drug use
Homosexual
Heterosexual
Blood Transfusion

Participants #
57
51
46
4

Participants %
39%
35%
32%
3%
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Table 3: Disease Characteristics
Health Status
Excellent
Very Good
Good
Fair
Poor

Participants#
11
33
62
33
6

Participants %
8%
23%
43%
23%
4%

Bodily Pain
None
Very mild
Mild
Moderate
Severe
Very severe

Participants #
37
28
19
42
14
5

Participants %
26%
19%
13%
29%
10%
3%

Days in Bed
0
1-20

Participants #
67
74

Participants %
46%
51%

Number of Hospitalizations
0
1-8

Participants #
92
51

Participants %
63%
35%

Disease Duration
Less than a month
One to six months
> 6 months but < 1 year
1-2 years
3-4 years
5 years or more

Participants #
1
4
4
14
27
92

Participants %
1%
3%
3%
10%
19%
63%

CD4 cell count
> 500
201-500
50-200
>50

Participants #
20
53
44
19

Participants %
14%
37%
30%
13%

30

(

Table 4: Medication regimen characteristics
Total number of med. (mean)
# of prescribed medication
1(monotherapy)
2
3
4
5
6

3.7

7
8

Participants#
6
30
41
24
25
12
6
1

Participants %
4%
21%
28%
17%
17%
8%
4%
1%

Medication Class
Antivirals
Protease Inhibitors
Antiinfectives

Participants #
143
73
82

Participants %
99%
50%
57%

Most freq. prescribed drugs
Epivir (3TC)
Stavudine (D4T)
Trimethoprim (Bactrim)
Zidovudine (AZT)
lndinavir (Crixivan)

Participants #
121
69
67
65
58

Participants %
83%
48%
46%
45%
40%

How long taking medication
Less than 1 month to 6 months
6 months to 1 year
1 to 2 years
more than 2 years

Participants #
49
26
26
42

Participants %
34%
18%
18%
29%

Freq. of medication use
2X per day
3X per day

Participants #
80
40

Participants %
55%
28%

# of Side effects
0 (none)
1-5
6 - 10
> 10

Participants #
38
46
40
34

Participants %
26%
32%
19%
24%
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Table 5: Patient - Provider Characteristics

Questions about Medications
Physician
Pharmacist
Nurse
Other HIV person

Participants #
132
45
43
39

Participants %
91%
31%
30%
.. 27%

Most Helpful Health Care Prov.
Physician
Nurse
Pharmacist
Other

Participants#
65
27
19
14

Participants%
45%
19%
13%
10%
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Table 6: Self-Reported 100°/o Adherence rates in the HIV population

Mean Adherence for

......,
......,

Medication #1 Medication #2 Medication #3 Medication #4

Past Week

69.66%

60.69%

51.03%

31.47%

Past Month

46.21%

46.21%

42.07%

25.87%

Past three months

41.38%

42.07%

35.86%

22.38%

Medication
Medication
Medication
Medication

#1 (first drug in a regimen)
#2 (second drug in a regimen)
#3 (third drug in a regimen)
#4 (fourth drug in a regimen)

*Past Week (self reported 0 doses missed (100% adherence) in the past week)
*Past Month (self reported 0 doses missed (100% adherence) in the past month)
*Past 3 Months (self reported 0 doses missed (100% adherence) in the past 3 months)

Table 6A: Percent of those who reported 0 or >=1 doses missed

#Doses Missed

Medication #1 Medication #2 Medication #3 Medication #4

Past Month (0 doses)

56.25%

56.52%

60.87%

71.11%

Past Month (>=1 doses)

43.48%

43.48%

39.13%

28.89%

w

.i::.

Medication
Medication
Medication
Medication

#1
#2
#3
#4

(first drug in a regimen)
(second drug in a regimen)
(third drug in a regimen)
(fourth drug in a regimen)

*Past Month (self reported 0 doses missed in the past month)
*Past Month (self reported >=1 doses missed in the past month)

TABLE 7A: Multiple regression analysis model for the dependent variable
Medication Adherence(% of doses taken, 0 - 100%) vs. the independent variable
group: patient characteristics

INDEPENDENT
VARIABLES

STANDARD
COEFFICIENT

STANDARD
ERROR

P-value

0.00016

0.00037

0.6769

#YRS. EDUCATION
(continuous)

0.00147

0.00113

0.1937

#PHYSIC. ASSIST.
(continuous)

-0.00036

0.00062

0.5640

RACE
_{_cate_g_orica!l

0.01958

0.00638

0.0027

EMPLOYMENT
_(cate_g_orica!l

0.01069

0.00650

0.1022

Jcat~orica!}_

-0.00084

0.00789

0.9157

HEALTH STATUS
(categorical)

-0.00762

0.00674

0.2610

AGE
_(continuoutl

ANNUAL INCOME

R 2 = 0.0898
F1,122= 1.72 (Pr> F 0.1103)
Dummy coding as 1 ' s and O' s were performed on every categorical variable used
in analysis.
AGE (continuous) 24- 57.
EDUCATION (continuous) 3 - 20.
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#OF PEOPLE FOR PHYSIC. ASSIST./PLACE TO STAY (continuous) 0-30.
RACE was coded as:
1- Non-White
0- White
EMPLOYEMENT was coded as:
1- Full/Part-time Employed
0- Not Employed.
ANNUAL INCOME was coded as:
1- <24,000
0- >25,000.
HEALTH STATUS was coded as:
1- ExcNG/Good
0- Fair/Poor.
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TABLE 7: Multiple regression analysis model for the dependent variable
Medication Adherence(% of doses taken, 0 - 99%) vs. the independent variable
group: patient characteristics

INDEPENDENT
VARIABLES

STANDARD
COEFFICIENT

STANDARD
ERROR

P-value

0.00027

0.00055

0.6268

0.00354

0.00173

0.0444

-0.00109

0.00086

0.2111

J_cat~orica!}_

0.04083

0.01030

0.0002

EMPLOYMENT
(categorical)

0.02019

0.01150

0.0836

_{_cat~orica!}

0.00044

0.01200

0.9705

HEALTH STATUS
__{_cat~orica!l

-0.01745

0.01081

0.1114

AGE
(continuous)
#YRS. EDUCATION
(continuous)
#PHYSICAL
ASSISTANCE.
_(continuous)
RACE

ANNUAL INCOME

R 2 = 0.2208
F 1,61

= 2.71 (Pr> F 0.0154)

Dummy coding as 1 ' s and O' s were performed on every categorical variable used
in analysis.
AGE (continuous) 24 - 57.
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EDUCATION (continuous) 3 - 20.
#OF PEOPLE FOR PHYSIC. ASSIST./PLACE TO STAY (continuous) 0-30.
RACE was coded as:
1- Non-White
0- White
EMPLOYEMENTwas coded as:
1- Full/Part-time Employed
0- Not Employed.
ANNUAL INCOME was coded as:
1- <24,000
0- >25,000.
HEALTH STATUS was coded as:
1- ExcNG/Good
0- Fair/Poor.
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TABLE 8A:Multiple regression analysis model for the dependent variable
Medication Adherence(% of doses taken, 0 - 100%) vs. the independent variable
group:Disease characteristics predictors

INDEPENDENT
VARIABLES

STANDARD
COEFFICIENT

STANDARD
ERROR

P-value

-0.00008

0.00099

0.9359

HOW LONG AGO
DIAGNOSED _{_cate_g_orical)

-0.00767

0.00945

0.4188

BODILY PAIN _icate_g_orica!)_

0.00428

0.00638

0.5035

P AINI INTERF. With
WORK_icate_g_orica!l_

-0.00173

0.00831

0.8356

CD4 CELL COUNT
_icate_g_orica!)_

0.01219

0.00756

0.1094

#DAYSINBED
_{_continuou~

R 2 = 0.0260
Fs,12s = 0.68 (Pr> F 0.6377)
Dummy coding as 1 's and O's were performed on every categorical variables used
in analysis.
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DAYS IN BED (continuous) 0 - 20.
HOW LONG AGO DIAGNOSED (categorical) was coded as:
0- >1 year
0- < 1 year
BODILY PAIN was coded as:
1- No Pain (None, Very Mild, Mild)
0- Pain (Moderate, Severe, Very Severe)
PAIN/INTERFERENCE WITH WORK was coded as:
1-No interf. (Not at all, A little bit, Moderately)
0- Yes interf. (Quite a bit, Extremely)
CD4 CELL COUNT was coded as:
1- > 500
0- < 500.
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TABLE 8:Multiple regression analysis model for the dependent variable
Medication Adherence(% of doses taken, 0 - 99%) vs. the independent variable
group:Disease characteristics predictors

INDEPENDENT
VARIABLES

STANDARD
COEFFICIENT

STANDARD
ERROR

P-value

#DAYSINBED
_(_continuous}_

-0.00053

0.00151

0.7273

HOW LONG AGO
DIAGNOSED J_cat~orica!l_

0.00557

0.01993

0.7806

BODILY PAIN _{_cate_g_orical}

0.00327

0.00901

0.7180

# HOSPITALIZATIONS
_{_continuous}_

-0.00042

0.00038

0.2770

-0.00128

0.00884

0.8850

CD4 CELL COUNT
J_cat~gorica!}_

R 2 = 0.0190
Fs,10= 0.27 (Pr> F 0.9273)
Dummy coding as 1's and O's were performed on every categorical variables used
in analysis.
DAYS IN BED (continuous) 0 - 20.
HOW LONG AGO DIAGNOSED (categorical) was coded as:
0- >1 year
0- < 1 year
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BODILY PAIN was coded as:
1-No Pain (None, Very Mild, Mild)
0- Pain (Moderate, Severe, Very Severe)
NUMBER OF HOSPITALIZATIONS (continuous)
CD4 CELL COUNT was coded as:
1- > 500
0- < 500.
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TABLE 9A:Multiple regression analysis model for the dependent variable
Medication Adherence(% of doses taken, 0-100%) vs. the independent variable
group: Medication regimen characteristics

INDEPENDENT
VARIABLES

STANDARD
COEFFICIENT

STANDARD
ERROR

P-value

TOTAL# of MEDICATION
_(continuous}_

0.00351

0.00291

0.2294

#OF SIDE EFFECTS
(continuous)

-0.00074

0.00030

0.0133

HOW LONG ON MED.
(cate_g_orical)

0.00026

0.00513

0.9591

R 2 = 0.0477
F 3, t34 = 2.24 (Pr > F 0.0867)
Dummy coding as 1 's and O's were performed on every categorical variable used
in analysis.
TOTAL# OF MEDICATION (continuous); 1 - 4.
TOTAL NUMBER OF SIDE EFFECTS (continuous); 0- 45.
HOW LONG ON MEDICATION was coded as:
0- <=1 year
0- >1 year
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TABLE 9:Multiple regression analysis model for the dependent variable
Medication Adherence (% of doses taken, 0 - 99%) vs. the independent variable
group: Medication regimen characteristics

INDEPENDENT
VARIABLES

STANDARD
COEFFICIENT

STANDARD
ERROR

P-value

0.00417

0.00446

0.3525

(continuou~

-0.00111

0.00049

0.0275

HOW LONG ON MED.
J_cate_g_orical)

-0.00559

0.00804

0.4895

TOTAL# of MEDICATION
J_continuou~

# OF SIDE EFFECTS

R 2 = 0.0703
F 3,1s = 1.89 (Pr > F 0.1386)
Dummy coding as 1 's and O's were performed on every categorical variable used
in analysis.
TOTAL# OF MEDICATION (continuous); 1 - 4.
TOTAL NUMBER OF SIDE EFFECTS (continuous); 0- 45.
HOW LONG ON MEDICATION was coded as:
0- <=1 year
0- >1 year
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TABLE 10: Stepwise Multiple Regression analysis for the dependent variable
Medication Adherence(% of doses taken, 0 - 100%) vs. the independent
variables.

Inde_I!_endent Variables R-S_g_uare

F-value

P-value

0.0071

0.081

0.3696

# of Medication
Ste.£_ 0

J_continuou~

# of Side Effects
Ste_Ql

J_continuou~

0.0403

3.87

0.0516

Ste.£_ 2

Health Insurance
_il=no O~e~

0.0724

3.85

0.0524

# of Children
Ste.£_3

J_continuou~

0.0937

2.58

0.1109

St~4

How long HIV+
J_l>=l _year 0<1 _y_earl

0.1195

3.19

0.0767
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TABLE lOA: Final model for Multiple regression analysis for the dependent
variable Medication Adherence (% of doses taken, 0 - 100%) vs. the
independent variables.

Independent
Variables

Standard
Coefficient

Standard
Error

P-value

# of Medication
J.continuous}_

0.00406

0.00239

0.0921

_icontinuous}_

-0.00075

0.00025

0.0035*

How long HIV+
_il>=l _year 0<1 _yeaij_

-0.01244

0.00764

0.1049

# of Children
J.continuous}_

-0.00021

0.00011

0.0464*

Health Insurance
_il =no O=_y_es}_

0.00886

0.00552

0.1104

# of Side Effects

R 2 = 0.1138
Fs,134 = 3.44 (Pr> 0.0059)
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DISCUSSION

The medication regimen prescribed for HIVI AIDS patients is described in the research
literature as complex and demanding, and consequently difficult for lifetime strict
adherence. Adherence to a complex medication regimen is a challenge for patients,
and requires patients' motivation and devotion to treatment. Non-adherence is
considered by some authors to be a behavioral problem. For a patient to stay adherent
to a complex, probably lifelong, antiretroviral treatment "requires change in patient
behavior" 29 · Non-adherence in HIV management is a major obstacle to improved
health status.
It is difficult to define a real degree of non-adherence in the study sample because we

do not have precise and accurate methods to measure patients' adherence to prescribed
medication regimen. Multiple regression analyses as well as Stepwise multiple
regression analysis was carried out on the total sample as well as on the smaller subs"cunple of the study participants who reported missing medication. This method did
not help to define more potential predictors of medication adherence.
When adherent study participants were compared with multiple ANOVA's to nonadherent study participants, they were similar. No significant differences were found
between the two groups, although the non-adherent sample had slightly more women,
more hospitalizations, longer duration of disease, and worse CD4 cell count.
Adherence was high in this study population. Perhaps, adherence rates were
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overestimated, or this population was highly motivated, and, with high social support,
they were adherent to the prescribed medication regimen.
A: Patient Characteristics

Potential predictors of medication adherence grouped as patient characteristics
include: age, education, race, employement, annual income, health status, and number
of people for physical assistance or place to stay. Model for the total sample was not
significant. Model which include sub-sample of non-adherent study participants, (0
doses missed were deleted), was significant. Only variables, race (Non-White) and
education showed positive association with medication adherence in this model.
B: Disease characteristics and
C: Medication regimen characteristics

Predictors grouped as disease characteristics, and medication regimen characteristics
did not show statistically significant association with variable medication adherence.
D: Final model; Stepwise Multiple Regression Analysis

Using Stepwise Multiple Regression Analysis the following variables were included in
the final model: Total number of medication (continuous), Number of side effects
(continuous), Number of children (continuous), Health insurance (categorical none vs.
some) and How long ago diagnosed as HIV positive (categorical l>=l year vs.O<l
year).
Variables which did not enter the model included: age (continuous), race (categorical
non-white vs. white), education (continuous), annual income (categorical <$24,000 vs.
>$25,000), employment (categorical full/part-time vs. not employed), number of
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family or friends for physical assistance or place to stay (continuous), bodily pain
(categorical

very

mild/mild/moderate

vs.

severe/very

severe),

number

of

hospitalizations (continuous), days in bed in a last 2 weeks (continuous), CD4 cell
count (categorical >=500 vs. <500), how long on HIV related medication (categorical
>=l year vs. <l year).
In the final model, unexpectedly, the number of medications did not show significant

association with medication adherence. This finding is consistent with the previous
research reported by Sing et al., 17 Baley et al., 21 Christensen et al., 40 and Sung et al. 42
For the better-fit variable total number of medication was transformed by squaring it,
but the final result was almost the same as before transformation. Also results for the
sub-sample was not significantly different from the results for the final model,
including total sample.
One of the aspects of the complexity of a prescribed regimen is the number of
medications in a regimen, as well as the frequency of dosing, number of side effects,
food requirements, taste, and cost. All this is true for the medication regimen
prescribed for HIVI AIDS patients. This study findings suggest that more complex
regimen, with larger nun1ber of medication does not necessarily lead to medication
non-adherence. This is illustrated in Figures 1 and 2. Previous research also reported
that it is most likely that it is not only the number of medication, but probably other
aspects of the regimen complexity, such as the frequency of medication use, number of
side effects, or perhaps nun1ber of psychological variables that contributes
significantly to the patients medication non-adherence. 17
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In the final model two variables showed negative statistically significant association

with medication adherence: number of side effects and number of children.
Previous research reported stable family situation as important and positive factor for
patients' medication adherence, but association between the number of children and
medication adherence was not reported. This study found negative association between
number of children and medication adherence. Perhaps people with children had more
duties including childcare and skip prescribed medication more frequently than people
without children did.
Number of side effects showed negative statistically significant association with
medication adherence. The higher number of side effects in the regimen the less likely
patients will adhere to such a regimen. This finding is consistent with the previous
research. Catz et al. 57 and Proctor et al.
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reported number and severity of side effects

in the prescribed regimen as a significant predictor of patients' medication nonadherence. Mehta et al. reported also that medication therapy with the number of side
effects usually results in poor adherence to prescribed regimen. 16
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CONCLUSION

The results of this research project demonstrate that the number of prescribed
antiretroviral medication may not predict patients' medication adherence. Patients on a
more complex antiretroviral medication regimen did not miss higher percent of
prescribed medication and we may not discriminate between adherent and nonadherent patients only based on a number of prescribed antiretroviral medications. All
this is consistent with previous research. Also variables number of side effects and
number of children showed negative statistically significant association with
medication adherence.

The study has the following benefits:
The advantages of a self-report, such as low cost, and fast and easy distribution,
probably make it a good choice to study and collect data about larger as well as smaller
populations. The relatively large study population, 145 patients, and the precise and
nonjudgmental questioning gives researchers a unique opportunity to explore
adherence issues in depth and to assess important and valuable information about
adherence behavior as well as a nun1ber of other important factors associated with
adherence in this population. Although the self-report is an indirect adherence
measure, it has been reported by some authors as a measure with higher sensitivity and
specificity over other measures.25 ' 35 A better understanding of adherence to a
prescribed antiretroviral medication regimen in this HN population may help us to
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develop intervention strategies, which would be valuable for this and other HIV
patients, and a number of other chronic illnesses that require lifelong treatment. The
results of this research will provide information about the patients' needs for health
care providers as well as for pharmaceutical companies and manufacturers.

The study has the following limitations:
Because these are self-reported data estimate of the number of doses missed in the
past month because of forgetfulness may not be exactly the number of doses missed.
Some patients simply do not want to report non-adherence; recall bias and
overestimation of adherence rate are real possibility in this type of data collection. 22 .24
Although numerous methods for measuring adherence exist; no instrument satisfied all
the necessary criteria to be accepted as gold standard to measure adherence rate. Data
was collected during '96-'97, when combined therapies were being just introduced as
a standard of care and at that time knowledge and infomrntion about the treatment
options of HIV positive individuals was limited. However, the recommended standard
of care is (HAART), a multiple drug therapy including potent protease inhibitors
drugs, other than drug combinations used previously. Study sample size was a
limitation for more in depth research about adherence rates in some subpopulation
groups, such as incarcerated HIV positive participants, or HIV positive women. Study
participants were mostly unemployed, without health insurance, and with long
duration of disease. Race distributions were not typical for HIV population, and
middle age White males were over sampled. Adherence was probably overestimated or
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(
study participants were maybe more adherent to prescribed medication regimen than
other, average HIV patients because they accepted to participate, and they already were
patients in clinic. Because they were patients on the clinics maybe they received
counseling about importance of medication adherence in HIVI AIDS management.
Study design was limitation for an estimate of the prevalence of non-adherence over
longer period of time.
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Managing Your Medications Questionnaire
Please answer the following questions thoughifully and completely. This questionnaire is
about how you tltink andfcel about the IiIV related medications that you are taking, ruul
about the different strategies that people use to take their m edicatio ns. It will take about
45 minutes for you toji.ll tltis out. You mayfill it out at home and mail it in or you may
return it to this clinic. When you turn it in, we will give you a gift certificate for $20 to
tlmnk youfor yo1Lr parlicipcition. If you have tile time to fill it out h ere, you ma y turn it in
to the person who _h anded it to you, and receive your gift certificate now.
CODE FOR THIS QUESTIONNAIRE:
i\) Whal are lhe first:~ letters of your mother's firs! name?

(1/1·3)

U} What is your birth date?

001001[]0
nun

dd

(l/~ ·D)

yy

SECTION I
BACKGROUND INFORMATION
The first sectton of this quesltonrwire asks about your background.

..... Please circle or fill in lhe correct response for each question.
1. \\Thal is your age?

DO years

2. What is your gender?

M

(l/10 -11)

I'

3. How would you describe your current health sl;:iius? (Please check onl' nnswer)
0 Excellent 0 Very Oood 0 Good 0 Fair 0 Poor

(1/12)

4. Which of the fo!Lowmg best describes your etlm!c background?

(L/13l

0
0

0
0

Vlhlte. non-Hispanic
Native American

0
0

Hispanic
A<;ian

5. How many years of cducatio.n have you finished?

Afric-.in American
OU1er'

OD

t1n4-1r.1

6. Do you currcnUy work either part-Ume or full lim1;:?

0

l' ull-timc

0

(1/lG)

0

Part-lime

Cam not currently employed

7. Do you live by yourst'lf or with 0U1cr people?

0

Dy myself

0

(I/Iii

Wi1h others

8. If you live with 0U1crs. how many (besides you} arc Jn your household?

00

9. If you live with others. what ts their relationship lo you? (Check all tliaL appl!J)
0 Husband or wife
0 Crandpnn::nts
0 Inli mate parlner
0 Children 1mdc.r age l 8
0 Other adults IS or older 0 Children over age 18
0 Parents
Un1t.it"'1,o;11v1.tf llJ-..odt.• f-.frv'V'l, t::l9:1t1

(
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{l/18--19)

flno-2s1

(

10. Do you have any children? lfso. how many? (/jnonc, p11L 0)

DD

(1/27 ·2.R)

l l . Do any of your adult children live nearby [within a half ho'ir drive)?

0

0

Yes

D

No

(1/29)

Nol applicabll:

12. How many of your family or friends cru1 you count on for cmolional suppolt?

DD

(1/:lO·:ll)

13. How many or your family or friends can you count on for llnanclal help? DO

(1/32-33)

14. How many or your fa~ or friends can you counl on for physical assistance,
or a place to stay? OU

(1/3'1.:!5]

15. Do you feel confident that your family or friends w!ll continue Lo hdp you with
your everyday needs'?

0
0
0
0
D

(l/36)

Vc1y confldcnt
Fairly confident
Somewhat confident
Less than somewhat confident
No1 ;it all confident

16. Tf you were to need more help with every day needs, do you feel confident that you.r family or
(l/37]
friends could provide it?

0

0
0
0
0

Very confident
Fairly confident
Somewhat confident
Less than somewhat confident
Not at all confident

17. !low many of your family & ftiends have you told abou l your HIV infection?

0

None

0

Less U1an half

0

About half

0

More than half

D

18. \Vhat type or health insurance coverage do you cmTcnUy have'?

0
0
0
0

NONE
Blue Cross
Ocean State
RIGHI\

0
0
0

0
0
0

HCHP
Other private lnsurer

HMO

0
0

0

O

(1/491

Less U1a.i1 $15,000
$15.000 lo $2-1.000
$25.000 to $31\,000
$35,000 to $44.000
45.000 or more

20. About how far do you live from this treatment

0
0
0

(1/3948)

Medicaid
Medicare
Other

19. Which of the following best estlmates your total (family) Income dunng U1e
past 12 months?

0
0
0

(1/381

All

ci~nler?

Within walking distance
Within a Len minute drive or less
Wit.hln a Lwenty minute drive or less
Within a (b!rty minute drive
More than thirty minutes away
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(l/00)

(
I

2J. When you have questions :iboul medications for your HIV lnfectitm. who do you
u s w11ly ask? (Pleas e check all tliaJ. apJ)ly)

n Pharmacist

0
LJ
0

Physician
SQCi<ll Worker
Nurse

D
0
0
0

(l/5 1·5Ul

Ol.her persons with HIV infection
Faml\y mcmbc:rs
Friends
Other; pkasc spcclly _

(1/59·76!

22. Which health c:arc provicter is most helpful to you in taking your medlcalions as d1n:clcd?

0
0
0
0
0

tl/79)

Nurse
Pliannadsl.
Physician
Socin.I Worker
Other; please specify

1211 201

23. rs U1ere someone living with you
met.licalions on time?

0

Yes

0

or close lo you who helps or reminds you to take your
(:l./21)

No

24. I fow much hodily pain have you had during lhe pasl four weeks?

0
0
0

0
0
0

None

Veiy mild
Mild

12/22)

Moderate
Severe
Very Severe

25. Durin!', lhe past 4 weeks. how much did pain interfere with your normal work (including both

work outside Lhe hoine and housework)?

0

Nol al all

0

A little bit

0

l2/2:ll

Moderately

D Quite a bit 0

Extr emely

26. During lhe pasl two weeks. how many days <lid you stny in bed all or mos!
of llie day? OD

12/24·25)

00

27. How many times have you been hospitalized in lhe pas( year? (If none. put OJ

28. These quest(ons are oJXJut how voufcc[ rutd how things have been. wWt
weeks.

tJO!l

\2/26-27)

dw ing the past 4

For ew:lt questfon. please give the one answer that comes closest to the WO.!J you have beenfeeling.
How rnuclt of U1e lime clwi.ng the pas! 4 weeks ...
NONE
01'' TIIB
TIMR

ALITl'LS
OF TUE

nrr

Tl~W.

SOM£
01' THE
TIME

~l·'b1d vou ·ree1 rtiw~f.fp:~~·?.':I?"'-: ··-.·--J'.~'F::K:::~o~~=-~~.,

O

D

b . Have you been a very ncivous
person?
Have you. fetl'so'iluiv-r1:rn 1hi'?

CJ '.'"":q,_~,:ra--

d. I lave you felt calm and peaceful?

O

AGOOO

MOS1'

AU.

8fT OFTIIB

OF THE
TIME

OF THE

TIME

o

o

0

0

·;rn--::..
11
.·.~~l7~u~4t?~~~~~~~-c,o:~t1;¥ e.:~~~~1~~~~~j5~;~-J~2 ;_i.·~c.·:~i. <· -: ~.

:c.

.

·~~~G .:r·

O

O

W:iJ\d y0i1;i;r.y~<f,~tjt§t~D$E©~-~:::;.:f?J~li,,!fy~i·~i1El~~~~~o ~
f. r-i ave you fell duwnhearled and
O
0
0
blue?
' g.' Did ;you .fc¢J:P9'?Nilµt~.~'f=;r... ·'":~~[] ·'>¥~?! EJ~;.-:/.!i G
1i . i-1·;1~c you G
een a happ);re~on? .. 0 ···-· O
0
t. rnc1you reet:nrca?
.
·· i{ }:";: :·~.'[] :' .;~~:, :D

ti ·

Ut\fr\!rsl:y oj Wv:>dc ls.land C199 ?
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=

·G ". - ti
~-

O

0

0

tJ ;:

o

.LJ

(2/2111

(2/JO)

0

' CJ :,~; ~ er··· ;::;rm

-0 . .

(2/28)

·o .. - -0

(2/311
(i/3'l)
t2/J3J

D
O

o

.0 . '- .,_EJ .
O
O
·o JJ

(2/:111
{i/J!}J

t2/ JGI

(

I
29. How long ago were you diugnosed as mv positive?

0
0

O

12/:17)

0

Less than a month
One lo six months

More than six months. bul less Uwn a year

30. How do you think you got your

I-nv

0
0

l to 2 ye_ars
3 to 4 years

5 years or more

lnfeclion?

l</38 -41)

Please check all thal apply

0
0

0
0
0

Injection (IV) drug use
Heterosexual cont.act
Homose.'\.ual c:onlact
Blood transfusion
Other:

[2/43-02)

3 I . What was your T cell count (CD4 counl) the last \.imc you were tested?

0

Greater than 500

0

201-500

0

50-200

Un.iv(. ·r:slry of Wvxlc Isla.Ni. C!9<J6

66

0

Less than 50

(2/63)

I
SECTION II
MEDICATION HISTORY
\VHICH OF Tl II.': FOi.LOWING MCDIC/fflONS ARE YOU TAl\.ING NOW?
- PLEASE CI II~Cr< ALL '!1li\T :\.Pl'LY:

0

0
0
0

AZT (Rclrovlr®, zidovudine)
DOI (Vidcx®. <.it<.lanoslne)

8D

DOC (Hiv!d®. zalcllablne)
D4T (Zeril(\SJ, stavu<.line)
3TC (Epivir®, lamivudine)
Saqulnavir (lnvfrase®)
Rilonavir (Norvir®)

0

Oilier:

0
0
0
0
0
0
0

lrn.linavlr (Crtxlvan®)
Trlmcthoprim or Sulfamethox.'1zole (Baclriin®, Septrn.®J
Glartthromycin (Blaxin®)
Dapsonc

Ftuconazolc (Dillucan®)
llr.tconazolc (SporanoA.'®)
H.ifabuUn (Mycobutin®)

---

We 'UH)uld like to ask you about each medicine that you are currenth1 taking. Please fill out
the following 2 page medicationformfor each medicine that you checked on tfte above list.

If you are currently taking 1 medication, Jill. out 2 pages.

if yot1 are curren!.41 taking 2 medications. fill out 4 pages.
+-

If you are cw1ertLly taklng :~ medications, fill out 6 pages.
if you are cwmrtUy taking more them 3 medications, pl.e ase JW out 6 pages and addilional
pages in the Supplement at the end of this questioMaire.

Pease go to page 12 after you have filled out these medica.tfon fonns. ,
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MEDICATION #1
MEDICINE NAM!!;_ _ _ _ _ _ _ _ ___ _ _ _ _ __
r:111 201

l.

2.

11liS medicine Is for:

(3/211

n

[l(V Infection

0
0

0

To Lreut or prevent PCP (Pn.e11moc;1slis carinii pne11mornaJ
To Lrcal or prevent fl.1Al (Mycobactcrium avlum complex) infccti<m
To treat or prevent fungal tnfectlons (Calldida or "thrush")

D
0

OU1Cr:

(3/?.2·4 IJ

Don't know

I low often do you take this medicine?

!J/42-f>ll)

D 1\vo limes a week

0
0

Three limes a week
Every olher day

0

'l\vo times a day
Three times a day
Four limes a day
Five times a day
Other:

0
0

011<:e a day

80
3.

(:J/51-701

Ilow long have you been laking Ulis medicalion?

4 lo 6 months
4.

During the [ast 3 month.s, have you ever stopped talang thls medication because you
felt better?

D
5.

Yl!:S

(J/71)

__ 6 monUis to l year
__ 1 Lo 2 years
__ more than 2 years

Less than l monU1
__ I lo 3 months

D

(3/721

NO

Duritlg the l gst .3 months. have you ever stopped laking lhls mecUcation be<-..ause you felt

worse?

0
6.

YES

D

0

YES

0

at times been careless about taking Ulis medlr.alion?

YES

D

(3/"f?>J

NO

(3/7GJ

NO

Dttring the last 3 months. have you ever taken le§,'l of tl1ls medicine than your doctor
prescribed because you felt worse?

0

(3/71.)

NO

During lite last 3 months, have you ever taken less of thls medicine U1an your dodor
prescribed because you felt better?

0
9.

(3/?'JJ

NO

Dw-ing lite last 3 months, b.ave you

DYES
8.

D

During the last .3 months, have you ever ror~ottcn to take thls medication?

0
7.

YF'..S

NO

68

(3/77)

(

I·
10. §incc. you began laking this merliralion. have you ever purµoscly:
NO

a) ta ken more of the metl!clne than your physician prcscribt'd?
bl taken less of lhe medicine than your physiciau prescribed?
c) tliscoulinued or stopped taking your mcdir.aUon?

0

0
0
0

0
0

(3/71l)
(3/7!1)
(:1/!lO]

.!Luefi.
l t. a) How many times have you discontinued your medication for more thaf) :-1 days'?

(4/ 1..2)

t~/3·lll

b) What were yo1Jr reasons for dlsconUnulng your mcdicatlon?
(Plr:ase check all that apply}

0

0
0
0
D
D

My doctor recommended it
Too many side effects
l didn't want to be reminded of my illness
Problems with Insurance cover.:1ge
I didn't think it was worlong

Other:----------

(t./9·28)

12. Sometimes IL is difficult to take prescribed medicine all lhe lime. Durl.n1U..fill...m1st week, bow
many times did you miss a dose of MEDICATION l? _ _ _
(4/29-3oJ
13. During the past month, about how many times did you miss a dose ofME:DlCATION i'?
(4/31 32)

14. Durin.g lhe past three months, about how many tlmes did you miss a dose MEDICATION 1?
(4/33·3~)

15. Please check any side e!Jecl(::>) you are having that you believe are caused by this mcdiclne:

D nausea
D dizziness
D vomltlng
D abdominal pain
0 diarrhea
D other:

0
D
0

D
D

shorlncss of breaU1
muscle aches

faugue
tingling in hands/feet
ntunbness in hands/feet

U11Jur..•1·sity ~{ Uhc~!•_. f\lUt)(l ~l99(i

69

o

l~/35

5-0J

headaches

B

an,'l:iety /worry

depression
rash
sensili\ity to sun

B

(4/51·70)

(

/
MEDICATION #2
Ml::lJIC!NP: t\1\ME_ _ _ _ _ _ _ _ _ - - - I.

·111i:;

rJ

80
00

2.

rnedielnc is for:

(5/211

HlV infection
To lrcal or prevent PCP (Pnewnocystis carirtff pneumonia)
To Lreat or prevent MA.! (Mycobaclcrium avtum complex) lnfccUon
To treat or prevc.11l fungal infections (CaJtd.ida or "thrush")
Other:k_n_o_.w_ _ _ _ __
Don't

How often do you take U11s medicine'?

0

0
D

lt>/42-50)

15/51-70)

3.

Ilow long have you been taklng this medication?
. _Less lh.an l month
__ 6 months to l year
__ l rn :; rnonlhs
__ I to 2 years
4 to 6 monlhs
__ more Uian 2 years

4.

During chc last 3 months, have you ever stopped laking this medication because you
felt better?

DYES

6.

D

D

Yr.S

D

(5/74)

(5/751

(S/7oJ

NO

During the last 3 mont1ts, have you ever !iilken less of this medicine than your doctor
prescribed because you felt worse?

0

(5/731

NO

During the last 3 mont~. have you ever taken less of Ulis medicine than your doclor
prescribed bc<;ause you felt better?
YES

15/721

NO

Dw·ing the last 3 months, have you at times been rareless abou( taking this medication?

0
9.

D

15/71)

NO

During the last 3 months. have you ever forgotten lo Lake Olis medicallon?

DYES

8.

D

During U1e last 3 months, have you ever stopped laking thLs medlcalion because you felt
worse?
DYES
0 NO

D n:s
7.

(5/22·4 I)

Two times a week
·ni.ree Limes a week
l::verv other day

D Onc~aday
0 Two limr~c; a day
0 Three limes a day
0 Four times a day
0 Five limes a dav
0 Other:----- - - - - -

5.

15/l 20)

NO

l!111vcrstt11 '11<hod.e /'(Jmvl. f}J!J9G
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f5/77J

(

I
10. Since ttou began takin</ U1is medication. have you ever purposely:

a) wken more of lhc medicine lhan your physi<'ian pr<'~<>cribcd?
bl la ken les!; of lhe medicine llian your physician prescribed?
c:) disconlinued or slopprd taki11~ your mcdicalion?

YES

NO

0
D

0
0
D

0

(5/78)

(5/791
(5/001

I[iws.

11. a) How many times have you diseontlnued your mcdfcaUon for more than :i days?

(6/ t-'.lJ

bl What were your reasons for discontinuing your mcd!calion'?

(6/3 SJ

Please check all Lil.al appl!f

D My doctor recommended il
0 Too many side effects
0 r didn'l wanl lo be reminded of my !llncss
0 Problems wiU1 lnsurancc coverage
0 I didn't lhlnk It was working
0 OU1er:

(6/0 211)

12. Sometimes il is difficult lo lake prescribed medicine all the time. During the past week, bow
many times did you miss a dose of Ml;:DICA110N 2? __ __
(G/29 -301
13. Durin.g the past month , about how many times did you miss a dose of MEDICATION 2?
-··- - -

(6/ll..:12)

14. During lhc past three months, about now many times did you miss a dose MEDICATION 2?
(6/33-341

15. Please check any side effer.t(sJ you are havl.ng thal you believe arc caused by lbis medicine:
(4/35 -50)

Onausea
0dizziness
Ovomlting
O abdominal pai11
Octtarrhea
Oother:

0 shortness of breath
0 muscle aches
0 fatigue
D tingling in hands/ feet
0 numbness ln hands/feel

0

0

0
,0
0

headaches

anxiety/wony
depression
rash
sensitivity lo sun
(G/Sl-70)
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MEDICATION #3
MEDJCINE NAME, _ _ _ _ _ _ __ _ __ __
1.

This

1111~ciicinc

is for:

(7/2l)

0 HlV inrccllon
0 To treal. 01· prevent PCP (Pneumocyslis carinii pneumonia)
0 To treat or prevent MAI (Mycollactcrlurn avium complex} inlcclion
0 To lreal or prevent fu ngal lnfccuons (Candida or "thrush")
0 OUit::r: _ _ __
lJ Oon'l know
2.

llow often do you take llils mec1icine'?

(7/42·50)

[7/5 1-70)

1\vo limes a week
Three times a week
C:very o~hc1· day
Onct:a day
Two times a day
Three urnes a day
Four limes a day
~·ive times a day

Other: · - - -- - - - --

How long have you been t.aking lliis medication?
_ _ Less lhan I month
_
6 months lo 1 year
1 lo 3 months
_
l to 2 years
_ _ 4 lo 6 months
__ more Uian 2 years

4.

During tile last 3 months, have you ever stopped lakini< lbis medlcalion because you
fell better?

0

YES

YES

{7/731

NO
(7/74)

NO

YES

0

NO

During the la.st 3 months, have you ever !aken less of th1s med!clnc than your doctor
prescribed because you felt better?

0
9.

0

(7/72)

During the last 3 months, have you al times bceu <.areless about taking this rnedlcauon'? (7/751

0
8.

0

f7/7U

NO

During IJie last 3 months, have you ever .fill:g9Jti>n to take this medication'?
DYES

7.

0

During the last 3 months, have you ever stopocd taking this medication because you felt
worse?

0
6.

(7/22·4 l)

0
0
0
0
0
0
0
0
0
3.

5.

(7/l-20)

YF..S

0

During the last 3 months, have you ever taken kss of this medicine than your doctor
prescriber! because you felt worse?

0

YES

0

!7/'/61

NO

NO

lh1focrslty o{U,l11x.fr tdt.ulil, Ql996
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HJ. Since uou began taking this medical!on. have you ever purposely:
a) ta ken more of ll1c medicine than your physician prcscril}ed?
bl l.akcn k:ss of l11c 1ncdlcinc than your ph}•slcian prescribed'?
cl discontinued or slopped t;iking your medit:allon?

Y£S

NO

0
0
0

0
0
0

flf"/li)

(7/791
(7 /tlOI

li!JC§..

11. a) How many times have you disconlim1cd your mtdlcalion for more than 3 days?

(H/111

b) What were your reasons for dlsconU[luing your medicallon?
Please check all lhat apply

0
0

0
0
0
0

[6/3·81

My doctor recommended lt
Too many side effects
I didn't want to be remirn.kd of my Illness
Problems with insurance covenige
I dldn't think it was working
(B/9·261

Other:-- - -- - - - - - -

12. Sometimes it is difficult to take prescribed medicine all the lime. Durin!! the past week, how
many times did you mlss ;;i dose of !1.1EDICATION 3? _ _ _
(S/2.9-30)
13. During the past month, about bow many times did you miss a dose of MED1CA'l10 3?
tH/31 ·32)

14. During the past three months, about how many times did you miss a dose M£DICA110N 3'?
(8/33-341

15. Please rheck any side effecl[s) you arc having 1.hat you believe arc caused by tills medicine:
(6/35-501

Onausea

Dshortness of breaU1

0dtzziness

0 muscle aches

Ovomiting
Oabdominal pain
Octiarrhea
Oothcr:

Oratigue
D tingling In hands/feel
D numbness ln hands/feet

0

0

headaches
anxiety/worry
depression
rnsh
senslliv!ly to sun

8

'0

(6/5 1-70)
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SUPPLEMENT TO SE CTION II
MEDICATION #4
MEDIC I NF: NAME_ _ _ _ _ _ _ _ _ _ _ _ _ _ __

l.

0
0
0
2.

ll5/SG)

Th.ls medicine is for:

0
0
0

(15/36-55)

HIV lnfectlon
To treal or prevent PCP (Pneumocyslis carinii µneumoniaJ
To Lreat or prevent MAI (Mycobactertum avium complex) infection
To treal or prevent funga l infections (Cundida or "thrush")
Olhcr: _ _ __
Don't know

How often do you take this medicine?

(1 5/57-?GJ
(15/77)

0 l\vo limes a week
0 111ree times a week
0 Every other day
D Once a day
0 1\vo limes a day
D 111ree Limes a day
D rOllf li mes a day
D Five limes a day

0
3.

4.

Olher: - --

- - -- - -

I low long have you been takin g this medication?
_
6 months to l year
l..e~s 1..han l monU1
_
l Lo 2ycars
l to 3 months
__ more than 2 years
4 to 6months

( 16/l 201

Durtng the last 3 months, have you ever slopped taking this medication because you felt
better?

001211

DYES
5.

0

NO

During the last 3 months. have you ever stopped taking thls medication because you felt
worse?

(16/7.2)

D YES

6.

YES

YES

(16/23)

NO

0

NO

Du ring the last 3 months. have you ever taken less of this medicine than your doctor pre·
1rn12s1
scribed because you felt better?

D YES
9.

0

Duri ng the last 3 months. have you al limes been careless about taking lh!s medicaUon?11i;/24J

0
8.

NO

Duling lhe last 3 months. have you ever forgotten to take lhls mediC'alion?

0
7.

0

0

NO

During the last 3 months. have you ever taken less of this medicine than your doctor pre·
scribed because you felt worse?
(lu/2ul

D YES

0

NO

74
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JO. Since you bcczan taking lb.ls medication, have you ever purposely:
YJ·:5

NO

taken more of the medicine than your
physlcla1L prescrib!'cl?
b) taken less of Ute mcrhrine than you r physician
prescribed?

D

D

(lti/UI

D

D

(16/".!H)

cl discontinued or stopped lalung your medication?

D

D

llG/29)

a)

11 .a) I low many limes have you discontinued your medication for more
than 3 days?

b) What were your reasons for disronUnulng your medir;ition?

(16/30-31)

(16/32·37)

Please check all l/1al. apply

0

0
0
0
D
0

My doctor recommended It
Too many side effects
I didn't want to be reminded of my illness
Problems with insurance coverage
I didn't think it was working
Othe r : - - - - - -- - --

(38 57]

12. Sometimes it is difficult to take prescribed medicine all t.he. lime. During the past week, bow
many times did you miss a dose of MEDLCATION 4? _ _ _
11s1sa-so1
13. During U1e past month, abou t how many times did you miss a dose of MEDICATION 4?
(tfi/GO GIJ

14. During U1e past three months, about how many times did you miss a close MEDiCA'llON 4?
(16/62-03)

15. Please check any side cffect(s) you are having Uml you believe arc caused by this medicine:
(16/64 ·~)

0
0
0
0

D
0

nausea
d1z7Jness
vomiting
abdominal pain
diarrhea
other:

o

shortness of brcalh
muscle aches
fatigue
tingling In hands/feel
numbness io hands/feel

B
0
0

0 headaches
0 an.xlety /worry
D depression
0 rash
0 sensitivity to sun
(!7/1-20)

l/nit'("r.di11 o/ flhock· lslwtf). tr:J9'J(i
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MEDICATION #5
MlWIC!NE Ni\M~---- - - - - - - - - - - - - -

I.

This medici!1c is for:

0
0
0
0
0

0

2.

117/~

To lrcat or prevent PCP IPneumocysCi.s ca.rinii pnewnonta)
To treat or prevent MAI (Mycobaclerium avlum complex) infeclion
To treat or prevent fungal JnfecUons (Candida or "thrush")
Other:-----------Don't !mow

(17/4~-61)

How often do you take this medicine?

0
0
0

I)

I IJV lnfecllon

[17/62)

'l\vo lime::; a week
·n1rce 1imes a week
Every olhcr day
Once a day
1Wo limes a day
Three \.imcs a day
Four Limes a day
Five Limes a day

B
0
0
0
0

3.

1.

llfl/1·20i

Other:---------

How long have you been taking this medJcalion?
Less Uian I monlh __ 6 months lo l year
__ I Lo 3 months
_ I to2year s
__ 4 lo 6 months
_
more Umn 2 years
DUiing the last 3 months, have you evc:r stopped taking this medical.ion b<:1:ausc you felt
bette r?

11 a1221

DYES
5.

r'E:s

NO

D

(18/24)

NO

D NO

During I he last 3 months, have you ever taken less of lhi::; medicine than your doctor pre·
(lts/201
scribed because you felt better?

D YF...S
9.

D

Oming lhe !ct.'>t 3 months. have you at times been careless aboul laking this medicalion'?oe12&1

D YES
8.

NO

During the Last 3 mon t h.'> , have you ever forgotten to take this medicaUon?

D
7.

D

Duling lhe last 3 months. have you ever slopped Laking this 1uedication because you felt
worse?
llB/23)

O ms
6.

[16/21)

D

NO

Durtng the last 3 months. have you ever taken less of lhts mcclicine than your doctor prescribed because you fell worse?
(18/271

DYES

1Jnil.oc·r,.;,t111 of Uh.ock l:;ftpt1I,

D

f\O

~1~11.>
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Hl. S ince yo u beqa n rnkin q this mcdieatlon. have you ever purposely:

n) ta krn more or the mt:c.licine I han your

YF:S

NO

0

0

08/281

0

0

(lB/291

0

0

llll/30}

phyi>ici;in prescribrd?
b) lnken less of the medicine limn }'OUf µhysiciall
prescribed?

c) disconUnuetl or stopped Lale.Ing your mcrtiralion?

~ 11.a) How many times have you 1.lisconUnucd your medit:alion for more
ll8/3l·32)

lhan :; days?
bl What were your reasons for dlsconlinuing your medication?
Please dwck all that apply

0
0
0

Mv doclor recommended ii
Too many side effects
I didn't wanl to be reminded of my illness
Problems wiU) insurance coverage
r didn't think it was worlctng
O t h e r : - - - - -- - - - -

B
0

(IS/33·381

(l6/39 58)

12. Sometimes it is difficult lo lake prescribed medicine all the time. Du ring t he past wee k, how
many times rlitl you nllss a dose of MEDICATION 5? __ _ _
!IS/59 ·601
13. During the past month, about how m any times did you mlss a dose ol'MEDICATION 5?
(tB/Gl-021

14. Duling the past three months, about how many times did you miss a dose Ml.W!CA110N 5?
illi/63·64)

15. Please check any side effeclls) you art> having lhal you believe are caused by this meditine:
(18/G5-80l

0
0
0

0
0
0

nausea
clizziness
vomlting
abdominal pain
diarrhea
other:

o. shortness of breath
0
0
0
0

muscle aches

fatigue
tingling in hands/feel

numbness in hands/feel

0
0
0
0
0

headaches
an.'Ciety/worry
depression

rash
sensltMly lll sun
fll)/l -201
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MEDICATION #6
MEDICINE NAME_ - - - - -- - - - --

l.

- - - -- -

'lhis mcclirine is for:

(19/:zl 4ll)
(19/•1 IJ

0 mv infection

D To treat

0
0

D

0
2.

or prevent PCP (Pneumocysti.s carinii pnewnonku
To treat or prevent MAI (Mycobaclerium aviwn complex} iufcclion
To !real or prevenL fungal infections (Candida or "lhrush")
OU1cr: - - - -·- - - -- - - - Don't know

How oflen do you lake Lllis medlcinc?

(19/62)

0 1\vo times a week
D Three times a week
0 Every 0U1er day
D Once a day
0 T\vo limes a day
0 Three Umes a dt=1y
0 Four limes a day
0 Five times a day
0 Othe.r:
3.

Ilow long have you been
_ _ Less lhan 1 month
__ 1 lo 3 months

4 to 6 months
4.

D

NO

0

NO
(20/24)

D NO

0

NO

During the last 3 mont hs. have you ever taken kss of (his med icine than your doctor prescribed because you felt better?
120/26!

D
9.

(20/2 LJ

During lh c last 3 months. have you at times been careless about taking this mcctienUon? t2012;;1

D YES
8.

Ulis medication?
_ _ 6 months lo l year
_ _ 1 to 2 years
_ _ more U1an 2 years

During the last 3 months. have you ever forgoll.en lo take U1is medication?

D YES
7.

Laki1\~

During U1c last 3 months, have you e\'Cr s topped taking lhls medication because you felt
worse?
(20/2:lJ

DYES
6.

[20/ 1-20)

During the last 3 months, have you ever s topped Laking lhis medication because you fell
better?
1201221

DYES
5.

( l9/12 ·6lJ

YP.:..'S

D

NO

During lhc last 3 month.<>. have you ever lakcn less of this medicine lhan your doctor prcscrihed because yo u fell won;e?
1201211

0

YES

D

NO
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10. S ince 1LQ!l..J:w9an taking lliis mcdicalion. h3vr you ,•vcr puqJosdy:

al tak.:n more of the medicine Lhan yo\1r
physician prescribed?
b) tak<'n less of U1c medicine than your pl1ysician
prescribed?
cl disronUn11ed or stopped taking your mc<lication?

+-

Yl~S

NO

0

0

1·20/'lRJ

0

0

(20/?9)

0

0

\20/30)

1 1.l'I) How many limes have you cltscon Unucd your medlralilin for more

l?ll/3 l-321

than 3 days?

bl

What were your rc;isons for
Please check all that apply

discomtnuln~ your medica llon?

(2.0/33·~81

0 My doctor recommended ll
0 Too many side effects
0 l didn't wanl to be renundcd of my illness
0 Problems with insurance coverage
0 r didn't l.hlnk il was working
0 Other:
12. Sometimes il is difficult to take pn·scribed medicine all lhc urnc. During th e past week, how
many times did you miss a dose of MEDICA"l10N 6? _
\21l/59·60J
13. !)urlng the past month, about ltow ntany times did you m..lss a dose ofMt:DlCJ\TlON 6?
(20/61-1$21

14. During Lhe past three months, auoul ho w many times did you miss a dose MF:D!Cf\'110N
6?
(~0/63·G-1l
15. Please check any side effccl(s) you arc having thal you believe are caused by this medicine:
120/ti5-SOI

0 nausea
0 dizziness
OvomiUng
0 abdominal pain
0 diarrhea
0 olher:

~ODO ~~:~~::~~l~~~rcalh
Un~ling in hands/feel

numbness in hands/feet

-------~-------

79

0 headacncs
0 amdcly/worry
0 dt:prr_ssion
0 rash
0 sensitivity to su n

-------·
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The SAS System
11 :15 Monday, May 7, 2001
Plot of COMP1MONTHL*QI1.
COMP1MONTHL
2.00

BA

Legend: A

=

obs, B = 2 obs, etc.
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NOTE: 100 obs had missing values.

80

50

60

(

The SAS System

Plot of COMP1MONTHL*HEALTH.
COMP1MONTHL
2.00

Legend: A

3

=

11

:15 Monday, May 7, 2001

1
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= 2 obs, etc.
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NOTE: 100 obs had missing values.
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The SAS System

4

11 :15 Monday, May 7, 2001
Plot of COMP1MONTHL*race.
COMP1MONTHL
2.00

Legend: A = 1 obs, B = 2 obs, etc.
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